HALO (Halozyme Therapeutics) Inventory Turnover: 0.48 (As of Mar. 2026)

What is Halozyme Therapeutics Inventory Turnover?

Halozyme Therapeutics HALO +0.98% 93 Inventory Turnover is 0.48 as of Mar. 2026. GuruFocus rates HALO with a GF Score™ of 93/100 and a GF Value™ of $90.93 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Halozyme Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $79 Mil. Halozyme Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2026 was $166 Mil. Halozyme Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.48.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Halozyme Therapeutics's Days Inventory for the three months ended in Mar. 2026 was 191.13.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Halozyme Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.44.

Halozyme Therapeutics (NAS:HALO) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Halozyme Therapeutics's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2026 )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
	=	165.971	/	79.238	*	365 / 4
	=	191.13

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Halozyme Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	165.971	/	376.708
	=	0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Halozyme Therapeutics Inventory Turnover Related Terms

Halozyme Therapeutics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Inventory Turnover can be seen below:

Halozyme Therapeutics Inventory Turnover Chart

Halozyme Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Inventory Turnover

Get a 7-Day Free Trial

1.42

1.81

1.69

1.18

1.44

Halozyme Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventory Turnover	Get a 7-Day Free Trial															0.32	0.27	0.30	0.43	0.48

93GF Score

Halozyme Therapeutics Inc HALO

Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Halozyme Therapeutics Inventory Turnover Calculation

Halozyme Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

	Inventory Turnover (A: Dec. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2025 )	/ (	(Total Inventories (A: Dec. 2024 )	+	Total Inventories (A: Dec. 2025 ))	/	count )
=	228.774	/ (	(141.86	+	176.475)	/	2 )
=	228.774	/	159.1675
=	1.44

Halozyme Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

	Inventory Turnover (Q: Mar. 2026 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2026 )	/ (	(Total Inventories (Q: Dec. 2025 )	+	Total Inventories (Q: Mar. 2026 ))	/	count )
=	79.238	/ (	(176.475	+	155.467)	/	2 )
=	79.238	/	165.971
=	0.48

Frequently Asked Questions Learn more about Inventory Turnover →

What does a Inventory Turnover of 0.48 mean?

Halozyme Therapeutics (HALO) has a Inventory Turnover of 0.48 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Halozyme Therapeutics and its competitors.

Is Halozyme Therapeutics' Inventory Turnover too high?

Halozyme Therapeutics' current Inventory Turnover is 0.48. Overall, Halozyme Therapeutics has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Halozyme Therapeutics' Inventory Turnover compare to KYMR and IBRX?

Halozyme Therapeutics' Inventory Turnover of 0.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventory Turnover for a Biotechnology company?

A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventory Turnover mean?

A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Inventory Turnover is 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Halozyme Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.93, compared to a current price of $81.56 — trading 10.3% below its estimated fair value. The current Inventory Turnover is 0.48. Halozyme Therapeutics' overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventory Turnover calculated?

Inventory Turnover is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Inventory Turnover is 0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued. The current stock price of $81.56 is trading 10.3% below its estimated GF Value™ of $90.93. GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.

Key valuation signals for HALO:

Inventory Turnover: 0.48
GF Value™: $90.93 vs. price of $81.56 (10.3% below fair value)
GF Score™: 93/100 with 3 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies KYMR IBRX PRAX TGTX CORT PCVX NUVL IMVT PTGX APGE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges HALO:Mexico 1HALO:Italy 0J2O:UK RV7:Germany

Address 12390 El Camino Real, San Diego, CA, USA, 92130

Website https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

93GF Score

Get the complete analysis for HALO

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$81.56

Price

$90.93

GF Value

View HALO Analysis

See Inventory Turnover data for all stocks →